| Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation. | Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation.
Singh S, Singh N, Gupta PSS, Panda SK, Dhamija I, Nathiya D, Kumar S, Sharma S., Free PMC Article | 07/31/2024 |
| High-throughput sequencing and in-silico analysis confirm pathogenicity of novel MSH3 variants in African American colorectal cancer. | High-throughput sequencing and in-silico analysis confirm pathogenicity of novel MSH3 variants in African American colorectal cancer.
Rashid M, Rashid R, Gadewal N, Carethers JM, Koi M, Brim H, Ashktorab H., Free PMC Article | 03/12/2024 |
| MSH3: a confirmed predisposing gene for adenomatous polyposis. | MSH3: a confirmed predisposing gene for adenomatous polyposis.
Villy MC, Masliah-Planchon J, Schnitzler A, Delhomelle H, Buecher B, Filser M, Merchadou K, Golmard L, Melaabi S, Vacher S, Blanluet M, Suybeng V, Corsini C, Dhooge M, Hamzaoui N, Farelly S, Ait Omar A, Benamouzig R, Caumette V, Bahuau M, Cucherousset J, Allory Y, Stoppa-Lyonnet D, Bieche I, Colas C. | 12/1/2023 |
| Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate-resistant human colorectal cancer cells. | Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate‑resistant human colorectal cancer cells.
Wang X, Qu Y, Xing R, Zhou J, Liu Y, Zhang H, Zhu J, Ma J, Cui X, Song T, Xing S, Ji G, Liu P, Sun W, Fu S, Meng X., Free PMC Article | 11/7/2023 |
| MSH2-MSH3 promotes DNA end resection during homologous recombination and blocks polymerase theta-mediated end-joining through interaction with SMARCAD1 and EXO1. | MSH2-MSH3 promotes DNA end resection during homologous recombination and blocks polymerase theta-mediated end-joining through interaction with SMARCAD1 and EXO1.
Oh JM, Kang Y, Park J, Sung Y, Kim D, Seo Y, Lee EA, Ra JS, Amarsanaa E, Park YU, Lee SY, Hwang JM, Kim H, Schärer O, Cho SW, Lee C, Takata KI, Lee JY, Myung K., Free PMC Article | 06/29/2023 |
| A large family with MSH3-related polyposis. | A large family with MSH3-related polyposis.
Aelvoet AS, Hoekman DR, Redeker BJW, Weegenaar J, Dekker E, van Noesel CJM, Duijkers FAM., Free PMC Article | 01/14/2023 |
| Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. | Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population.
Salo-Mullen EE, Maio A, Mukherjee S, Bandlamudi C, Shia J, Kemel Y, Cadoo KA, Liu Y, Carlo M, Ranganathan M, Kane S, Srinivasan P, Chavan SS, Donoghue MTA, Bourque C, Sheehan M, Tejada PR, Patel Z, Arnold AG, Kennedy JA, Amoroso K, Breen K, Catchings A, Sacca R, Marcell V, Markowitz AJ, Latham A, Walsh M, Misyura M, Ceyhan-Birsoy O, Solit DB, Berger MF, Robson ME, Taylor BS, Offit K, Mandelker D, Stadler ZK., Free PMC Article | 03/26/2022 |
| Coordinated roles of SLX4 and MutSbeta in DNA repair and the maintenance of genome stability. | Coordinated roles of SLX4 and MutSβ in DNA repair and the maintenance of genome stability.
Young SJ, West SC., Free PMC Article | 10/2/2021 |
| EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer. | EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
Mohammadpour S, Goodarzi HR, Jafarinia M, Porhoseingholi MA, Nazemalhosseini-Mojarad E. | 02/6/2021 |
| Genetic Polymorphism of Mismatch Repair Genes and Susceptibility to Prostate Cancer. | Genetic Polymorphism of Mismatch Repair Genes and Susceptibility to Prostate Cancer.
Khooshemehri P, Jamaldini SH, Ziaee SAM, Afshari M, Sattari M, Narouie B, Sotoudeh M, Montazeri V, Sarhangi N, Hasanzad M. | 02/2/2021 |
| Inflammation-Associated Microsatellite Alterations Caused by MSH3 Dysfunction Are Prevalent in Ulcerative Colitis and Increase With Neoplastic Advancement. | Inflammation-Associated Microsatellite Alterations Caused by MSH3 Dysfunction Are Prevalent in Ulcerative Colitis and Increase With Neoplastic Advancement.
Munakata K, Koi M, Kitajima T, Tseng-Rogenski S, Uemura M, Matsuno H, Kawai K, Sekido Y, Mizushima T, Toiyama Y, Yamada T, Mano M, Mita E, Kusunoki M, Mori M, Carethers JM., Free PMC Article | 09/26/2020 |
| The Human DNA Mismatch Repair Protein MSH3 Contains Nuclear Localization and Export Signals That Enable Nuclear-Cytosolic Shuttling in Response to Inflammation. | The Human DNA Mismatch Repair Protein MSH3 Contains Nuclear Localization and Export Signals That Enable Nuclear-Cytosolic Shuttling in Response to Inflammation.
Tseng-Rogenski SS, Munakata K, Choi DY, Martin PK, Mehta S, Koi M, Zheng W, Zhang Y, Carethers JM., Free PMC Article | 08/22/2020 |
| The genotype frequency distribution of rs26279 (A>G) in MSH3 was found to be significantly different between idiopathic male infertility and control (p < 0.05), as well as azoospermia. | The association of four SNPs in DNA mismatch repair genes with idiopathic male infertility in northwest China.
Zhao X, Mu C, Ma J, Dai X, Jiao H. | 04/18/2020 |
| Study suggests the SNPs rs12513549, rs33013, and rs6151627 in MSH3 are associated with the risk of acute adverse events (AEs). Therefore, these polymorphisms may be potential independent biomarkers for predicting AEs and prognosis in rectal cancer patients receiving postoperative CRT. | Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy.
Yang J, Huang Y, Feng Y, Li H, Feng T, Chen J, Yin L, Wang W, Wang S, Liu Y, Song Y, Li Y, Jin J, Tan W, Lin D., Free PMC Article | 12/21/2019 |
| MSH2-MSH3 not only stimulates pol beta to copy through the repeats but also enhances formation of the flap precursor for expansion. | Crosstalk between MSH2-MSH3 and polβ promotes trinucleotide repeat expansion during base excision repair.
Lai Y, Budworth H, Beaver JM, Chan NL, Zhang Z, McMurray CT, Liu Y., Free PMC Article | 09/8/2018 |
| The role of MSH3 in 11 Lynch Syndrome patients with truncating MSH6 germline variants and an unexplained MSH2 protein loss.Heterozygous MSH3 defects alone do not seem to induce a Lynch Syndrome phenotype | Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
Morak M, Käsbauer S, Kerscher M, Laner A, Nissen AM, Benet-Pagès A, Schackert HK, Keller G, Massdorf T, Holinski-Feder E. | 07/21/2018 |
| MSH3 was frequently inactivated by promoter methylation and its mRNA and protein expression correlated with the primary tumor stage in nasopharyngeal carcinoma. | Inactivation of MSH3 by promoter methylation correlates with primary tumor stage in nasopharyngeal carcinoma.
Ni H, Jiang B, Zhou Z, Yuan X, Cao X, Huang G, Li Y., Free PMC Article | 04/21/2018 |
| Msh3-/- cells are severely defective for CTG*CAG repeat expansions but show full activity on contractions. Msh3 overexpression led to high expansion activity and elevated levels of MutSbeta complex, indicating that MutSbeta abundance drives expansions. Expression of 2 Msh3 polymorphic variants at normal levels showed no detectable change in expansions. These polymorphisms primarily affect Msh3 protein stability, not ac... | MutSβ abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions.
Keogh N, Chan KY, Li GM, Lahue RS., Free PMC Article | 12/2/2017 |
| Findings indicate that carriers of the MSH5 rs707939 T allele, the MSH2 rs6544991 C allele, the MSH3 rs6151627 and rs6151670 G alleles, and the MSH3 rs7709909 T allele have poor toxicity tolerance to platinum-based chemotherapy in non-small cell lung cancer patients. | Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients.
Liu JY, Qian CY, Gao YF, Chen J, Zhou HH, Yin JY., Free PMC Article | 10/28/2017 |
| MSH3 is probably a modifier of disease progression in Huntington's disease. | Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S, TRACK-HD investigators, REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ. | 09/9/2017 |
| data suggest that MSH3 mutations represent an additional recessive subtype of colorectal adenomatous polyposis | Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis.
Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, Kirfel J, Tafazzoli A, Horpaopan S, Uhlhaas S, Stienen D, Friedrichs N, Altmüller J, Laner A, Holzapfel S, Peters S, Kayser K, Thiele H, Holinski-Feder E, Marra G, Kristiansen G, Nöthen MM, Büttner R, Möslein G, Betz RC, Brieger A, Lifton RP, Aretz S., Free PMC Article | 05/13/2017 |
| Three polymorphisms in MSH3 were associated with variation in somatic instability in myotonic dystrophy type 1. | A polymorphism in the MSH3 mismatch repair gene is associated with the levels of somatic instability of the expanded CTG repeat in the blood DNA of myotonic dystrophy type 1 patients.
Morales F, Vásquez M, Santamaría C, Cuenca P, Corrales E, Monckton DG. | 01/28/2017 |
| Our meta-analysis results demonstrated that MSH3 rs26279 G > A polymorphism is associated with an increased risk of overall cancer, especially for the colorectal cancer and breast cancer. | MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis.
Miao HK, Chen LP, Cai DP, Kong WJ, Xiao L, Lin J., Free PMC Article | 09/17/2016 |
| The mismatch-binding protein MutS beta, a heterodimer of MSH2 and MSH3, activates ATR in response to DNA double-strand breaks. | The Mismatch-Binding Factor MutSβ Can Mediate ATR Activation in Response to DNA Double-Strand Breaks.
Burdova K, Mihaljevic B, Sturzenegger A, Chappidi N, Janscak P. | 04/30/2016 |
| Data show that single nucleotide polymorphisms in MutS homolog 3 (MSH3) had an impact on the chemotherapy response and prognosis of advanced non-small cell lung cancer (NCSLC) patients who were treated with platinum-based chemotherapy. | Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Xu XL, Yao YL, Xu WZ, Feng JG, Mao WM. | 04/2/2016 |